• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

timothy.spelman@unimelb.edu.au

Credentials


Position
Research Statistician
Department of Surgery
ORCID

0000-0001-9204-3216

Dr Timothy Spelman

Research Statistician
Department of Surgery

604 Scholarly works
8 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Corrigendum to “Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study” [Multiple Sclerosis and Related Disorders Vol 106; Feb 2026; Article Number 106885] (Multiple Sclerosis and Related Disorders (2026) 106, (S2211034825006236), (10.1016/j.msard.2025.106885))
    DOI: 10.1016/j.msard.2026.107131
  • 2025

    Research grants (ARC, NHMRC, MRFF)

    Australian SPine Registry (ASPIRE) - Collecting, Analysing, Evaluating and Protecting Australians After Spine Surgery
  • 2023

    Research contracts (non-grants)

    Effect of Subcutaneous Tirzepatide Once-Weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA): A Randomized, Double-Blind, Placebo-Controlled Trial
  • 2021

    Journal article

    Associations of Disease-Modifying Therapies with COVID-19 Severity in Multiple Sclerosis
    DOI: 10.1212/WNL.0000000000012753
  • 2016

    Research Grant

    Centre for Research Excellence in Total Joint Replacement Optimising Outcomes, Equity, Cost Effectiveness and Patient Selection (Opus)
  • 2015

    Journal article

    Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis
    DOI: 10.1002/ana.24339
  • 2013

    Journal article

    Sex as a determinant of relapse incidence and progressive course of multiple sclerosis
    DOI: 10.1093/brain/awt281
Timothy Spelman

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Ocrelizumab Discontinuation vs. Continuation After Safety Events: Comparative Insights from MSBase.
    DOI: 10.2174/011570159X448901251228053318
  • 2026

    Journal article

    A longitudinal study of children identifies antibody Fc-mediated functions and antigen targets of immunity to Plasmodium vivax malaria
    DOI: 10.1016/j.immuni.2026.02.003
  • 2026

    Journal article

    QuantiFERON-CMV Monitoring Post-Allogeneic Hematopoietic Stem Cell Transplantation Is Dynamic and Predictive of Immediate Cytomegalovirus Outcomes
    DOI: 10.1111/tid.70152
  • 2026

    Journal article

    Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial
    DOI: 10.1093/cid/ciaf409
  • 2026

    Journal article

    Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study
    DOI: 10.1016/j.msard.2025.106885
  • 2026

    Journal article

    Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry
    DOI: 10.1007/s00415-026-13632-4
  • 2026

    Journal article

    Treatment Patterns, Prognostic Factors and Survival for ALK-Positive Advanced NSCLC In Australia: Results From the Australasian Thoracic Cancers Longitudinal Cohort Study and Biobank (AURORA)
    DOI: 10.1016/j.jtocrr.2025.100924
  • 2026

    Journal article

    Perceived stress in mothers of children with and without islet and coeliac autoimmunity in the ENDIA study
    DOI: 10.1007/s00125-025-06584-3

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224